• Please log in or register to access this feature.

Editorial

You have free access to this content

Is Vitamin C Intake too Low in Dialysis Patients?

  1. Jochen G. Raimann1,
  2. Nathan W. Levin1,
  3. Ronald G. Craig2,3,
  4. William Sirover4,
  5. Peter Kotanko1,
  6. Garry Handelman5

Article first published online: 29 OCT 2012

DOI: 10.1111/sdi.12030

Issue

Seminars in Dialysis

Seminars in Dialysis

Volume 26, Issue 1, pages 1–5, January/February 2013

Additional Information

How to Cite

Raimann, J. G., Levin, N. W., Craig, R. G., Sirover, W., Kotanko, P. and Handelman, G. (2013), Is Vitamin C Intake too Low in Dialysis Patients?. Seminars in Dialysis, 26: 1–5. doi: 10.1111/sdi.12030

Author Information

  1. 1

    Renal Research Institute, New York

  2. 2

    Department of Basic Sciences and Craniofacial Biology, New York University, New York

  3. 3

    Department of Periodontology and Implant Dentistry, New York University, New York

  4. 4

    Cooper Medical College, Camden, New Jersey

  5. 5

    Clinical Lab and Nutrition Science, University of Massachusetts, Lowell, Lowell, Massachusetts

* Address correspondence to: Garry Handelman, University of Massachusetts, Lowell, Lowell, MA 01854, Tel.: +1 978 934 4503, or e-mail: garry_handelman@uml.edu.

Publication History

  1. Issue published online: 24 JAN 2013
  2. Article first published online: 29 OCT 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (108K)

References

  • 1
    Lind J: A Treatise on the Scurvy in Three Parts. London: Printed by G. Pearch and W. Woodfall for S. Crowder, D. Wilson and G. Nicholls, T. Cadell, T. Becket and Co., 1753
  • 2
    Kramer JGH: Medicina castrensis: Bewährte Artzney wider die im Feld und Guarnisons unter Soldaten grassirende Kranckheiten. Nuremberg: Endter, 1736
  • 3
    Nishikimi M, Yagi K: Molecular basis for the deficiency in humans of gulonolactone oxidase, a key enzyme for ascorbic acid biosynthesis. Am J Clin Nutr 54(6 Suppl):1203S–1208S, 1991
  • 4
    Johnston CS: The antihistamine action of ascorbic acid. Subcell Biochem 25:189–213, 1996
  • 5
    Hemila H, Herman ZS: Vitamin C and the common cold: a retrospective analysis of Chalmers’ review. J Am Coll Nutr 14(2):116–123, 1995
  • 6
    Institute of Medicine (U.S.): Panel on Dietary Antioxidants and Related Compounds. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids : a report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Washington, D.C.: National Academy Press, 2000
  • 7
    Richter A, Kuhlmann MK, Seibert E, Kotanko P, Levin NW, Handelman GJ: Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients. Nephrol Dial Transplant 23(6):2058–2063, 2008
  • 8
    Baker EM, Hodges RE, Hood J, Sauberlich HE, March SC, Canham JE: Metabolism of 14C- and 3H-labeled L-ascorbic acid in human scurvy. Am J Clin Nutr 24(4):444–454, 1971
  • 9
    Banerjee S, Chakrabarty AS: Anaemia and its relation with iron metabolism in scorbutic monkeys. Indian J Med Res 53(9):835–848, 1965
  • 10
    Banerjee S, Chakrabarty AS: Utilization of iron by scorbutic guinea pigs. Blood 25:839–844, 1965
  • 11
    Fidler MC, Davidsson L, Zeder C, Walczyk T, Hurrell RF: Iron absorption from ferrous fumarate in adult women is influenced by ascorbic acid but not by Na2EDTA. Br J Nutr 90(6):1081–1085, 2003
  • 12
    Hallberg L, Brune M, Rossander L: The role of vitamin C in iron absorption. Int J Vitam Nutr Res Suppl 30:103–108, 1989
  • 13
    Brise H, Hallberg L: Effect of ascorbic acid on iron absorption. Acta Med Scand Suppl. 376:51–58, 1962
  • 14
    Mazur A: Role of ascorbic acid in the incorporation of plasma iron into ferritin. Ann N Y Acad Sci 92:223–229, 1961
    Direct Link:
  • 15
    Mazur A, Baez S, Shorr E: The mechanism of iron release from ferritin as related to its biological properties. J Biol Chem 213(1):147–160, 1955
  • 16
    Hankes LV, Jansen CR, Schmaeler M: Ascorbic acid catabolism in Bantu with hemosiderosis (scurvy). Biochem Med. 9(3):244–255, 1974
  • 17
    Bothwell TH, Bradlow BA, Jacobs P, Keeley K, Kramer S, Seftel H, Zail S: Iron metabolism in scurvy with special reference to erythropoiesis. Br J Haematol 10:50–58, 1964
    Direct Link:
  • 18
    Goldberg A: The enzymic formation of haem by the incorporation of iron into protoporphyrin; importance of ascorbic acid, ergothioneine and glutathione. Br J Haematol 5(2):150–157, 1959
    Direct Link:
  • 19
    Lochhead AC, Goldberg A: Transfer of iron to protoporphyrin for haem biosynthesis: role of ascorbic acid and glutathione. Lancet 2(7097):271–272, 1959
  • 20
    Sirover WD, Siddiqui AA, Benz RL: Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study. Ren Fail 30(9):884–889, 2008
  • 21
    Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C: Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10(Suppl 6):44–47, 1995
  • 22
    Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F: Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. J Nephrol 13(6):444–449, 2000
  • 23
    Sezer S, Ozdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M: Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Artif Organs 26(4):366–370, 2002
    Direct Link:
  • 24
    Deira J, Diego J, Martinez R, Oyarbide A, Gonzalez A, Diaz H, Grande J: Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J Nephrol 16(5):703–709, 2003
  • 25
    Keven K, Kutlay S, Nergizoglu G, Erturk S: Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 41(6):1233–1239, 2003
  • 26
    Attallah N, Osman-Malik Y, Frinak S, Besarab A: Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47(4):644–654, 2006
  • 27
    Deved V, Poyah P, James MT, Tonelli M, Manns BJ, Walsh M, Hemmelgarn BR: Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 54(6):1089–1097, 2009
  • 28
    Finkelstein FO, Juergensen P, Wang S, Santacroce S, Levine M, Kotanko P, Levin NW, Handelman GJ: Hemoglobin and plasma vitamin C levels in patients on peritoneal dialysis. Perit Dial Int 31(1):74–79, 2010
  • 29
    Wang S, Geraci G, Kuhlmann MK, Levin NW, Handelman GJ: Chemical reactions of vitamin C with intravenous-iron formulations. Nephrol Dial Transplant 23:120–125, 2008
  • 30
    Handelman GJ: New insight on vitamin C in patients with chronic kidney disease. J Ren Nutr 21(1):110–112, 2011
  • 31
    Friedman PA, Coutermarsh BA, Kennedy SM, Gesek FA: Parathyroid hormone stimulation of calcium transport is mediated by dual signaling mechanisms involving protein kinase A and protein kinase C. Endocrinology 137(1):13–20, 1996
  • 32
    Pearce SH, Thakker RV: The calcium-sensing receptor: insights into extracellular calcium homeostasis in health and disease. J Endocrinol 154(3):371–378, 1997
  • 33
    Fain O: Musculoskeletal manifestations of scurvy. Joint Bone Spine 72(2):124–128, 2005
  • 34
    Iwasaki M, Manz MC, Taylor GW, Yoshihara A, Miyazaki H: Relations of serum ascorbic acid and alpha-tocopherol to periodontal disease. J Dent Res 91(2):167–172, 2011
  • 35
    Rahmati MA, Craig RG, Homel P, Kaysen GA, Levin NW: Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis 40(5):983–989, 2002
  • 36
    Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35(3):469–476, 2000
  • 37
    Deicher R, Ziai F, Habicht A, Bieglmayer C, Schillinger M, Horl WH: Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis. Nephrol Dial Transplant 19(9):2319–2324, 2004
  • 38
    Handelman GJ: Vitamin C deficiency in dialysis patients – are we perceiving the tip of an iceberg? Nephrol Dial Transplant 22(2):328–331, 2007
  • 39
    Zhang K, Liu L, Cheng X, Dong J, Geng Q, Zuo L: Low levels of vitamin C in dialysis patients is associated with decreased prealbumin and increased C-reactive protein. BMC Nephrol 12:18, 2011
  • 40
    Wang AY, Sea MM, Ip R, Law MC, Chow KM, Lui SF, Li PK, Woo J: Independent effects of residual renal function and dialysis adequacy on dietary micronutrient intakes in patients receiving continuous ambulatory peritoneal dialysis. Am J Clin Nutr 76(3):569–576, 2002
  • 41
    Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS: Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 41(8 Pt 1):1135–1138, 1995
  • 42
    Bohm V, Tiroke K, Schneider S, Sperschneider H, Stein G, Bitsch R: Vitamin C status of patients with chronic renal failure, dialysis patients and patients after renal transplantation. Int J Vitam Nutr Res 67(4):262–266, 1997
  • 43
    Morena M, Cristol JP, Bosc JY, Tetta C, Forret G, Leger CL, Delcourt C, Papoz L, Descomps B, Canaud B: Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant 17(3):422–427, 2002
  • 44
    Salyer WR, Keren D: Oxalosis as a complication of chronic renal failure. Kidney Int 4(1):61–66, 1973
  • 45
    Salyer WR, Hutchins GM: Cardiac lesions in secondary oxalosis. Arch Intern Med 134(2):250–252, 1974
  • 46
    Zazgornik J, Balcke P, Rokitansky A, Schmidt P, Kopsa H, Minar E, Graninger W: Excessive myocardial calcinosis in a chronic hemodialyzed patient. Klin Wochenschr 65(2):97–100, 1987
  • 47
    Wells CG, Johnson RJ, Qingli L, Bunt-Milam AH, Kalina RE: Retinal oxalosis. A clinicopathologic report. Arch Ophthalmol 107(11):1638–1643, 1989
  • 48
    Abuelo JG, Schwartz ST, Reginato AJ: Cutaneous oxalosis after long-term hemodialysis. Arch Intern Med 152(7):1517–1520, 1992
  • 49
    Hoffman GS, Schumacher HR, Paul H, Cherian V, Reed R, Ramsay AG, Franck WA: Calcium oxalate microcrystalline-associated arthritis in end-stage renal disease. Ann Intern Med 97(1):36–42, 1982
  • 50
    Hoppe B, Kemper MJ, Bokenkamp A, Portale AA, Cohn RA, Langman CB: Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 56(1):268–274, 1999
  • 51
    Worcester EM, Nakagawa Y, Bushinsky DA, Coe FL: Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure. J Clin Invest 77(6):1888–1896, 1986
  • 52
    Elder TD, Wyngaarden JB: The biosynthesis and turnover of oxalate in normal and hyperoxaluric subjects. J Clin Invest 39:1337–1344, 1960
  • 53
    Millan MT, Berquist WE, So SK, Sarwal MM, Wayman KI, Cox KL, Filler G, Salvatierra O Jr, Esquivel CO: One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation 76(10):1458–1463, 2003
  • 54
    Tomson CR, Channon SM, Parkinson IS, Morley AR, Lennard TW, Parrott NR, Laker MF: Plasma oxalate concentration and secondary oxalosis in patients with chronic renal failure. J Clin Pathol 41(10):1107–1113, 1988
  • 55
    Franssen CF: Oxalate clearance by haemodialysis – a comparison of seven dialysers. Nephrol Dial Transplant 20(9):1916–1921, 2005
  • 56
    Briggs M: Letter: Vitamin-C-induced hyperoxaluria. Lancet 1(7951):154, 1976
  • 57
    Friedman AH, Charles NC: Retinal oxalosis in two diabetic patients. Am J Ophthalmol 78(2):189–195, 1974
  • 58
    Marcus SL, Petrylak DP, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H: Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells. Am J Clin Nutr 54(6 Suppl):1292S–1297S, 1991
  • 59
    Lynch SR, Seftel HC, Torrance JD, Charlton RW, Bothwell TH: Accelerated oxidative catabolism of ascorbic acid in siderotic Bantu. Am J Clin Nutr 20(6):641–647, 1967
  • 60
    Brenner BM, Rector FC: Brenner & Rector’s the kidney, 8th edn. Philadelphia: Saunders Elsevier, 2008
  • 61
    National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47(5 Suppl 3):S11–S145, 2006
  • 62
    Petrarulo F, Giancaspro V: Intravenous ascorbic acid in haemodialysis patients with functional iron deficiency. Nephrol Dial Transplant 15(10):1717–1718, 2000
  • 63
    Tarng DC, Huang TP: A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 13(11):2867–2872, 1998
  • 64
    Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC: Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 55(6):2477–2486, 1999
View Full Article (HTML) Get PDF (108K)